*Corresponding author:
Archana S Gurjar, Department of Pharmaceutical Chemistry, Prin KM Kundnani College of Pharmacy, 23 Jote Joy, R. S. Marg, Cuffe Parade, Mumbai, 400 005, IndiaReceived: November 16, 2018; Published: December 04, 2018
DOI: 10.26717/BJSTR.2018.11.002140
To view the Full Article Peer-reviewed Article PDF
BACE1 plays critical role in the formation of neurotoxic β-amyloid (Aβ) peptides in brain and so is regarded as an ideal drug design target for Alzheimer’s disease. With this perspective, we have designed BACE1 inhibitors, specifically substituted aryl ureido analogues. Docking studies revealed interactions with the crucial catalytic Aspartate dyad of BACE1 enzyme. In silico ADME studies predicted favourable drug like properties for these analogues. Molecular docking results were in consensus with the pharmacological screening of the synthesized analogues. Overall results indicate that analogue 4c and 4d exhibit equivalent BACE1 enzyme inhibition.
Keywords : BACE1; Aryl Ureido Analogues; Molecular Docking; in Silico ADME; In Vitro; FRET Assay
Introduction| Results and Discussion| Conclusion| Experimental Section| Acknowledgment| References|